Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Lantern Pharma Inc. LTRN
$5.40
+$0.01 (0.19%)
На 18:02, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
62661254.00000000
-
week52high
6.59
-
week52low
4.05
-
Revenue
0
-
P/E TTM
-4
-
Beta
0.64070700
-
EPS
-1.23000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 20:00
Описание компании
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 11 мар 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 02 ноя 2021 г. |
| HC Wainwright & Co. | Buy | 07 окт 2021 г. | |
| Colliers Securities | Buy | Buy | 28 июл 2020 г. |
| EF Hutton | Buy | 01 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Kreis Leslie W. | D | 164137 | 40586 | 08 ноя 2022 г. |
| Kreis Leslie W. | D | 536163 | 132575 | 08 ноя 2022 г. |
| Kreis Leslie W. | D | 71774 | 17748 | 08 ноя 2022 г. |
| Kreis Leslie W. | D | 463658 | 100380 | 08 ноя 2022 г. |
| Kreis Leslie W. | D | 271193 | 58711 | 08 ноя 2022 г. |
| Fletcher Aaron G.L. | D | 164137 | 40586 | 08 ноя 2022 г. |
| Fletcher Aaron G.L. | D | 536163 | 132575 | 08 ноя 2022 г. |
| Fletcher Aaron G.L. | D | 71774 | 17748 | 08 ноя 2022 г. |
| Fletcher Aaron G.L. | D | 463658 | 100380 | 08 ноя 2022 г. |
| Fletcher Aaron G.L. | D | 271193 | 58711 | 08 ноя 2022 г. |
Новостная лента
ProPhase Labs Discloses 8.4% Position in LTRN / Lantern Pharma After Q3 Results
24/7 Wall Street
22 ноя 2022 г. в 22:31
Fintel reports that ProPhase Labs, Inc. has filed a 13G form with the SEC disclosing ownership of 910,000 shares of Lantern Pharma Inc. (LTRN). This represents 8.4% of the company.
Lantern Pharma to Present at the ThinkEquity Conference on Wednesday, October 26 at 1:00 p.m. ET
Business Wire
21 окт 2022 г. в 07:00
DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.
Lantern Pharma to Present at The MicroCap Rodeo Presents The Windy City Roundup 2022 on Wednesday, October 12 at 11:00 a.m. ET
Accesswire
11 окт 2022 г. в 16:00
DALLAS, TX / ACCESSWIRE / October 11, 2022 / Lantern Pharma Inc. (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning ("M.L.
Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-284 for Mantle Cell Lymphoma at the Society of Hematologic Oncology Annual Meeting
Business Wire
23 сент 2022 г. в 08:50
DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will present preclinical data on the potency of Lantern's drug candidate LP-284 for mantle cell lymphoma (MCL) and several other non-Hodgkin's lymphomas at the Society of Hematologic On
Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-184 for Pancreatic Cancer at the AACR Special Conference for Pancreatic Cancer
Business Wire
14 сент 2022 г. в 08:50
DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will present positive preclinical data on the in vivo efficacy of its drug candidate LP-184 for pancreatic cancer at the American Association for Cancer Research (AACR) Special Conferen